Product Details
| Product Name:
(R)-Equol |
CAS No.:
221054-79-1 |
| Purity:
99.59% |
Supply Ability:
10g |
| Release date:
2026/04/22 |
Product Introduction
Bioactivity
| Name | (R)-Equol |
| Description | (R)-Equol ((+)-Equol) is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively. |
| In vitro | (R)-Equol produced a dose-dependent inhibitory effect on the invasive ability of MDA-MB-231 cells, and this inhibitory effect was obvious at the highest test concentration (50 μM).Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035) [2]. |
| In vivo | In animals, (R)-Equol significantly reduces the number of palpable tumors over time compared to controls (P=0.002). The number of palpable tumors per rat in the (R)-Equol-fed group is significantly lower than in rats treated with S-(-)equol (P=0.008). (R)-Equol-fed animals exhibit 43% fewer tumors than the control group, with this difference being highly statistically significant (P=0.004). The number of tumors per tumor-bearing animal is significantly lower in (R)-Equol-fed animals compared to controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol-fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) compared to controls (9.9±1.4 mg). Feeding the (R)-Equol diet also results in significantly increased tumor latency (P=0.003) [3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (412.76 mM), Sonication and heating are recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (16.51 mM), Sonication is recommended.
|
| Keywords | progestogenReceptor | progestogen Receptor | Inhibitor | inhibit | EstrogenReceptor | Estrogen Receptor/ERR | Estrogen Receptor | ERβ | ERα | Equol | (R)-Equol | (R)Equol | (R) Equol |
| Inhibitors Related | Tamoxifen | Mifepristone | Estradiol | Astragaloside IV | Bisphenol B | Bisphenol Z | Mequinol | Phthalic acid | Ethisterone | Alpha-Estradiol | Ferrous Bisglycinate | Cholesterol |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Multi-Target Compound Library | NO PAINS Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$35.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
|
|
$15.00
|
|
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-02 |
|
|
$1.00
|
VIP7Y
|
Career Henan Chemical Co
|
2019-12-27 |
United States